Vol. 5 No. 10 (2025)
Reimbursement Reviews

Cabozantinib

decorative image of the issue cover

Published October 6, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cabozantinib, oral tablets (60 mg, 40 mg, or 20 mg).
  • Indication: Adults with locally advanced or metastatic extrapancreatic or pancreatic neuroendocrine tumours who have received at least 1 prior therapy.